Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 4, Pages e002056
Publisher
BMJ
Online
2021-04-12
DOI
10.1136/jitc-2020-002056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- (2020) Regina M. Myers et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
- (2020) Peter A. Riedell et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
- (2020) Samantha Jaglowski et al. BLOOD
- Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
- (2020) Marcelo C. Pasquini et al. BLOOD
- Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
- (2020) Paolo Strati et al. BLOOD
- Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
- (2020) Adam S. Kittai et al. BLOOD
- Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
- (2020) N. Nora Bennani et al. BLOOD
- Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
- (2020) Max Topp et al. BLOOD
- Corticosteroids Do Not Influence the Efficacy and Kinetics of CAR-T Cells for B-Cell Acute Lymphoblastic Leukemia
- (2020) Shuangyou Liu et al. BLOOD
- Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs
- (2020) Karl M. Kilgore et al. BLOOD
- Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
- (2020) Veronika Bachanova et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
- (2020) Carlos R. Bachier et al. JOURNAL OF CLINICAL ONCOLOGY
- How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies
- (2020) Joshua A. Hill et al. BLOOD
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma
- (2019) Matthew J. Frigault et al. BLOOD
- CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY BY BASELINE TUMOR BURDEN IN ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL
- (2019) R.T. Maziarz et al. HEMATOLOGICAL ONCOLOGY
- BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL
- (2019) M. Trněný et al. HEMATOLOGICAL ONCOLOGY
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
- (2019) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Real World Experience of Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cells Targeting CD19 in Patients with Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
- (2019) Marcelo Pasquini et al. Clinical Lymphoma Myeloma & Leukemia
- Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
- (2019) Veronika Bachanova et al. Clinical Lymphoma Myeloma & Leukemia
- Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective
- (2019) Hongbo Yang et al. BLOOD
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
- (2019) Mazyar Shadman et al. BLOOD
- Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
- (2019) Sunita Dwivedy Nasta et al. BLOOD
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
- (2019) Jason R. Westin et al. BLOOD
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT
- (2019) Carlos R. Bachier et al. BLOOD
- Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective
- (2019) Hongbo Yang et al. BLOOD
- A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
- (2019) Peter A. Riedell et al. BLOOD
- Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies
- (2019) Christopher R. Manz et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimizing CAR-T Cell Manufacturing Processes During Pivotal Clinical Trials
- (2019) Seshu Tyagarajan et al. Molecular Therapy-Methods & Clinical Development
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- (2018) David Porter et al. Journal of Hematology & Oncology
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
- (2018) Frederick Lundry Locke et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
- (2018) Jeremy S. Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- (2018) Reith R Sarkar et al. JNCI-Journal of the National Cancer Institute
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now